I
iSpecimen
Biotech & Life Sciences · Lexington, United States · Founded 2012 · IPO 2021
Marketplace for human biospecimens, providing researchers with the samples they need from the patients they want MoreLess
iSpecimen operates an innovative platform that connects researchers with a diverse network of biospecimen providers, facilitating the acquisition of high-quality biological samples essential for medical research and development. Serving academic institutions, pharmaceutical companies, and diagnostic labs, iSpecimen operates in the life sciences and healthcare markets. The business model revolves around a marketplace approach, where researchers can search, request, and obtain biospecimens from various providers. Revenue is generated through transaction fees and service charges for sample procurement and data management. The platform ensures compliance with regulatory standards and offers a streamlined process for both researchers and providers, enhancing the efficiency of medical research.
Keywords: biospecimen, medical research, healthcare, life sciences, marketplace, academic institutions, pharmaceutical companies, diagnostic labs, regulatory compliance, data management.
Talent graph
iSpecimen's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on iSpecimen's cap table
Sourced from Dealroom's funding and investor records.

Global footprint
Where iSpecimen has talent and traffic
team presence
Market sentiment
What the market is saying about iSpecimen
An AI-synthesized read of the highest-engagement posts about iSpecimen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See iSpecimen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.